Is that what Sustainable Earning stands for?: Pear Therapeutics Inc. (PEAR)

At the time of writing, Pear Therapeutics Inc. [PEAR] stock is trading at $1.98, up 4.21%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PEAR shares have gain 3.12% over the last week, with a monthly amount drifted -26.39%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 21, November 2022, Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference. In a post published today on Yahoo Finance, Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ET.

From an analyst’s perspective:

Pear Therapeutics Inc. [NASDAQ: PEAR] stock has seen the most recent analyst activity on January 26, 2022, when BofA Securities initiated its Neutral rating and assigned the stock a price target of $5. Previously, Credit Suisse started tracking the stock with Outperform rating on January 20, 2022, and set its price target to $11. On January 03, 2022, BTIG Research initiated with a Buy rating and assigned a price target of $12 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $13 on December 29, 2021. Chardan Capital Markets initiated its recommendation with a Buy and recommended $16 as its price target on December 22, 2021.

For the past year, the stock price of Pear Therapeutics Inc. fluctuated between $1.34 and $14.60. Currently, Wall Street analysts expect the stock to reach $5.11 within the next 12 months. Pear Therapeutics Inc. [NASDAQ: PEAR] shares were valued at $1.98 at the most recent close of the market. An investor can expect a potential return of 158.08% based on the average PEAR price forecast.

Analyzing the PEAR fundamentals

According to Pear Therapeutics Inc. [NASDAQ:PEAR], the company’s sales were 4.08 billion in the recent quarter, which represents an 211.40% jump. Gross Margin for this corporation currently stands at -24.36% with Operating Margin at -2511.53%, Pretax Margin comes in at -1548.05%, and Net Margin reading is -1548.05%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8600 points at the first support level, and at 1.7400 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0800, and for the 2nd resistance point, it is at 2.1800.

Pear Therapeutics Inc. [PEAR] reported earnings per share of $0.04 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.25/share, meaning a difference of $0.29 and a surprise factor of 116.00%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.17 per share as compared to estimates of -$0.24 per share, a difference of $0.07 representing a surprise of 29.20%.

Ratios To Look Out For

It is important to note that Pear Therapeutics Inc. [NASDAQ:PEAR] has a current ratio of 2.10. Also, the Quick Ratio is 3.93, while the Cash Ratio stands at 3.70. Considering the valuation of this stock, the price to sales ratio is 166.98, the price to book ratio is 9.45.

Transactions by insiders

We now turn our attention to insider trading, which in the past 3 months has resulted in 0 insider buyings of 0 shares and 18 insider sellings of 1,382,377 shares. Recent insider trading involved 5AM Partners IV, LLC, 10% Owner, that happened on Nov 15 when 63773.0 shares were sold. 10% Owner, 5AM Partners IV, LLC completed a deal on Nov 14 to sell 12128.0 shares. Meanwhile, 10% Owner 5AM Partners IV, LLC sold 29380.0 shares on Nov 11.